Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.
暂无分享,去创建一个
James I. Cohen | Gary Nesbit | E. Neuwelt | L. Muldoon | J. Delashaw | G. Nesbit | Leslie L Muldoon | Edward A Neuwelt | R. Nixon | Randal R Nixon | Peter Varallyay | Johnny Delashaw | James I Cohen | Annie Petrillo | Doris Rink | P. Várallyay | A. Petrillo | Doris Rink | Annie Petrillo | J. Cohen | Doris Rink
[1] D. Kraemer,et al. Association of Total Dose Intensity of Chemotherapy in Primary Central Nervous System Lymphoma (Human Non-Acquired Immunodeficiency Syndrome) and Survival , 2001, Neurosurgery.
[2] C R Wirtz,et al. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. , 2001, AJNR. American journal of neuroradiology.
[3] W. Yuh,et al. Functional Magnetic Resonance Imaging Using Iron Oxide Particles in Characterizing Head and Neck Adenopathy , 2000, The Laryngoscope.
[4] R. Edelman,et al. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. , 2000, Clinical radiology.
[5] R Weissleder,et al. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. , 2000, Radiology.
[6] New MRI Contrast Agent for Labeling of Tumor-Associated Macrophages that Stimulate Tumor Angiogenesis , 2000 .
[7] B. Thompson,et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma , 1999, Journal of magnetic resonance imaging : JMRI.
[8] E. Neuwelt,et al. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. , 1999, AJNR. American journal of neuroradiology.
[9] R Weissleder,et al. Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent , 1999, Journal of magnetic resonance imaging : JMRI.
[10] J Keegan,et al. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography , 1999, Journal of magnetic resonance imaging : JMRI.
[11] B Quesson,et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance , 1999, Magnetic resonance in medicine.
[12] C Delalande,et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. , 1999, AJNR. American journal of neuroradiology.
[13] S. Heiland,et al. Verbessern superparamagnetische Kontrastmittel die MR- tomographische Abgrenzbarkeit experimenteller Gliome? , 1998, Der Radiologe.
[14] P. Mergo,et al. MRI in focal liver disease: A comparison of small and ultra‐small superparamagnetic iron oxide as hepatic contrast agents , 1998, Journal of magnetic resonance imaging : JMRI.
[15] J. Bulte,et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation , 1998, Journal of Neuroscience Research.
[16] E. Neuwelt,et al. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.
[17] M. Hartmann,et al. [Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas?]. , 1998, Der Radiologe.
[18] B. Bonnemain,et al. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. , 1998, Journal of drug targeting.
[19] B. Tombach,et al. Hepatic MRI with SPIO: detection and characterization of focal liver lesions , 1998, European Radiology.
[20] E. Neuwelt,et al. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. , 1997, Neurosurgery.
[21] M. Harisinghani,et al. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations , 1997, Journal of magnetic resonance imaging : JMRI.
[22] Yoshimi Anzai,et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent , 1997, Journal of magnetic resonance imaging : JMRI.
[23] R Weissleder,et al. Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[24] E. Neuwelt,et al. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. , 1996, Neurosurgery.
[25] R Weissleder,et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. , 1996, AJNR. American journal of neuroradiology.
[26] R. Weissleder,et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. , 1995, The American journal of pathology.
[27] C Zimmer,et al. MR imaging of phagocytosis in experimental gliomas. , 1995, Radiology.
[28] B. Marincek,et al. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. , 1995, Radiology.
[29] J. Szumowski,et al. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. , 1995, The American journal of pathology.
[30] P. Jacobs,et al. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.
[31] R. Weissleder,et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. , 1994, Neurosurgery.
[32] R Weissleder,et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. , 1988, Radiology.